Abstracts tagged "SLE"

Abstract Number: 562 • 2013 ACR/ARHP Annual Meeting
The Knock-Out Of TWEAK Receptor/Fn14 Ameliorates Lupus Nephritis In MRL/Lpr Mice
Yumin Xia¹, Leal Herlitz², Simona Gindea¹, Jing Wen¹, Rahul Pawar¹, Alexander Misharin³, Harris R. Perlman⁴, Ping Wu⁵, Jennifer Michaelson⁵, Linda Burkly⁵ and Chaim Putterman⁶, ¹Albert Einstein College of Medicine, Bronx, NY, ²The Department of Pathology, Columbia University Medical Center, New York, NY, ³Medicine, Division of Rheumatology, Northwestern University, Chicago, IL, ⁴Northwestern University, Chicago, IL, ⁵Biogen Idec, Cambridge, MA, ⁶The Division of Rheumatology, Albert Einstein College of Medicine, Bronx, NY
Background/Purpose: Renal mesangial cells, podocytes, and tubular cells express Fn14, the sole confirmed receptor for the tumor necrosis factor (TNF)-family member cytokine TWEAK (TNF-like weak…
Abstract Number: 2703 • 2013 ACR/ARHP Annual Meeting
An Intronic CR2 Polymorphism Associated With Systemic Lupus Erythematosus Alters CTCF Binding and CR1 Expression
Jian Zhao¹, Brendan M. Giles², Rhonda L. Taylor³, Gabriel A. Yette², Kara M. Lough², Lawrence J. Abraham³, Hui Wu⁴, Patrick M. Gaffney⁵, Jennifer A. Kelly⁶, Kenneth M. Kaufman^7,8, John B. Harley^9,10, Carl D. Langefeld¹¹, Elizabeth E. Brown¹², Jeffrey C. Edberg¹³, Robert P. Kimberly¹⁴, Daniela Ulgiati³, Betty P. Tsao¹ and Susan A. Boackle¹⁵, ¹Division of Rheumatology, Department of Medicine, David Geffen School of Medicine University of California Los Angeles, Los Angeles, CA, ²University of Colorado School of Medicine, Aurora, CO, ³University of Western Australia, Perth, Western Australia, Australia, ⁴Rheumatology, David Geffen School of Medicine University of California Los Angeles, Los Angeles, CA, ⁵Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁶Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁷U.S. Department of Veterans Affairs Medical Center, Cincinnati, OH, ⁸1Center for Autoimmune Genomics and Etiology and Rheumatology Division, Cincinnati Children’s Hospital Medical Center and the University of Cincinnati, Cincinnati, OH, ⁹Division of Rheumatology and The Center for Autoimmune Genomics & Etiology, University of Cincinnati, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ¹⁰US Department of Veterans Affairs Medical Center, Cincinnati, OH, ¹¹Department of Biostatistical Sciences, Wake Forest School of Medicine, Winston-Salem, NC, ¹²University of Alabama at Birmingham, Birmingham, AL, ¹³Division of Clinical Immunology and Rheumatology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, ¹⁴Clinical Immun & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ¹⁵Medicine/Rheumatology, University of Colorado School of Medicine, Aurora, CO
Background/Purpose: Systemic lupus erythematosus (SLE) is characterized by the production of antibodies to nuclear antigens, which form immune complexes that deposit in tissues and cause…
Abstract Number: 1607 • 2013 ACR/ARHP Annual Meeting
Two Year Follow-Up On Biologics Use In 13 Centers- Data From The International Registry For Biologics In Systemic Lupus Erythematosus
Ronald F. van Vollenhoven¹, Melinda Mild², Søren Jacobsen³, S. Bernatsky⁴, Daniel J. Wallace⁵, Sang-Cheol Bae⁶, Manuel Ramos-Casals⁷, Francisco J. García-Hernández⁸, R. Ramsey-Goldman⁹, Andrea Doria¹⁰, Marta Mosca¹¹, Michelle A. Petri¹², M Ayala-Gutiérrez¹³, J.G. Hanley¹⁴ and for The SLICC group¹⁵, ¹Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), the Karolinska Institute, Stockholm, Sweden, ²Department of medicine, Karolinska Institutet, Stockholm, Sweden, ³Department of Rheumatology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark, ⁴Divisions of Rheumatology and Clinical Epidemiology, McGill University Health Centre, Montreal, QC, Canada, ⁵Cedars-Sinai Medical Center, Los Angeles, CA, ⁶Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ⁷Laboratorio de Enfermedades Autoinmunes Josep Font, Hospital Clínic, Barcelona, Spain, ⁸Internal Medicine, Hospital Virgen del Rocío, Sevilla, Spain, ⁹Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, ¹⁰Rheumatology Unit - Department of Medicine, University of Padova, Padova, Italy, ¹¹Rheumatology Unit, University of Pisa, Pisa, Italy, ¹²Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ¹³Unidad de Enfermedades Autoinmunes, Servicio de Medicina Interna, Hospital Carlos Haya, Malaga, Spain, ¹⁴Division of Rheumatology, Halifax, NS, Canada, ¹⁵Department of Medicine, the Karolinska Institute, Stockholm, Sweden
Background/Purpose: Only one biologic agent has been approved for use in SLE, but some are used off-label in various settings. To obtain systematic information regarding…
Abstract Number: 1039 • 2013 ACR/ARHP Annual Meeting
Risk Of High-Grade Cervical Dysplasia In Women With Systemic Inflammatory Diseases
Seoyoung C. Kim¹, Robert J. Glynn², Edward Giovannucci³, Sonia Hernandez-diaz⁴, Jun Liu⁵, Sarah Feldman², Elizabeth W. Karlson⁶, Sebastian Schneeweiss⁷ and Daniel H. Solomon^8,9, ¹Div. of Pharmacoepidemiology and Pharmacoeconomics, Div. of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ²Brigham and Women's Hospital, Boston, MA, ³Harvard School of Publich Health, Boston, MA, ⁴Harvard School of Public Health, Boston, MA, ⁵Division of Pharmaoepidemiology, Brigham and Women's Hospital, Boston, MA, ⁶Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ⁷Division of Pharmacoepidemiology, Brigham and Women's Hospital, Boston, MA, ⁸Division of Pharmacoepidemiology, Harvard Medical School, Brigham and Women's Hospital, Division of Rheumatology, Division of Pharmacoepidemiology, Boston, MA, ⁹Division of Rheumatology, Brigham and Women's Hospital, Boston, MA
Background/Purpose: Human papillomaviruses (HPV) are causes of high-grade cervical dysplasia and cervical cancer. Persistent HPV infection, the major risk factor for cervical cancer, is associated…
Abstract Number: 571 • 2013 ACR/ARHP Annual Meeting
Protective Effect Of Inducible Adeno-Associated Virus Mediated IL-2 Gene Therapy On Tissue Damages In Lupus-Prone Mice
Masayuki Mizui¹, Tomohiro Koga², Linda Lieberman³, Jessica Beltran³, Mark C. Johnson⁴, José C. Crispin², Roland Tisch⁴ and George C. Tsokos⁵, ¹Division of Rheumatology, Department of Medicine,, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, ²Medicine/Rheumatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, ³Division of Rheumatology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, ⁴Department of Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, NC, ⁵Rheumatology, Beth Israel Deaconess Medical Center/Harvard Medical School, Boston, MA
Background/Purpose: IL-2 plays critical roles not only in immune responses but also in peripheral tolerance. Impairment of IL-2 production has been linked to the development…
Abstract Number: 2674 • 2013 ACR/ARHP Annual Meeting
Vitamin D Deficiency Is Common and Associated With Increased C-Reactive Protein In Children With Lupus: An Atherosclerosis Prevention In Pediatric Lupus Erythematosus Substudy
Angela B. Robinson¹, Vin Tangpricha², Eric Yow³, Reut Gurion⁴, Grace McComsey⁴ and Laura E. Schanberg⁵, ¹Pediatric Infectious Disease, Rheumatology and Geographic Medicine, Rainbow Babies and Children's Hospital / Case Medical Center, Cleveland, OH, ²Medicine, Emory University School of Medicine, Atlanta, GA, ³Biostatistics, Duke Clinical Research Institute, Durham, NC, ⁴Pediatric Infectious Diseases, Rheumatology, and Geographic Medicine, Rainbow Babies and Children's Hospital / Case Medical Center, Cleveland, OH, ⁵Pediatrics, Duke University Medical Center, Durham, NC
Background/Purpose: Epidemiologic associations suggest vitamin D may play a role in inflammation and progression of atherosclerosis. Using frozen serum, carotid intima medial thickness (CIMT) measurements,…
Abstract Number: 1611 • 2013 ACR/ARHP Annual Meeting
Off-Label Use Of Rituximab For Systemic Lupus Erythematosus in Europe: Limited Use Mostly In Refractory Patients
Ronald F. van Vollenhoven¹, Melinda Mild², Andrea Doria³, T. Dörner⁴, Gianfranco Ferraccioli⁵, Frederic Houssiau⁶, T.W.J. Huizinga⁷, David A. Isenberg⁸, László Kovács⁹, Guillermo Ruiz-Irastorza¹⁰, Danilo Squatrito¹¹, Alexandre Voskuyl¹², Marta Mosca¹³, G D Sebastiani¹⁴, Murat Inanç¹⁵, Gabriella Szücs¹⁶, Søren Jacobsen¹⁷, A. Castro¹⁸ and for The IRBIS-EMA group¹⁹, ¹Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), the Karolinska Institute, Stockholm, Sweden, ²Department of medicine, Karolinska Institutet, Stockholm, Sweden, ³Rheumatology Unit - Department of Medicine, University of Padova, Padova, Italy, ⁴Charité University Medicine Berlin, Berlin, Germany, ⁵Division of Rheumatology, Institute of Rheumatology and Affine Sciences, Catholic University of the Sacred Heart, Rome, Italy, ⁶Department of Rheumatology, Université catholique de Louvain, Brussels, Belgium, ⁷Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁸Centre for Rheumatology Research, Rayne Building, 4th Floor, Centre for Rheumatology, Department of Medicine, University College London, London, United Kingdom, ⁹Department of Rheumatology, University of Szeged, Szeged, Hungary, ¹⁰Autoimmune Diseases Research Unit, Department of Internal Medicine, BioCruces Health Research Institute, Hospital Universitario Cruces, University of the Basque Country, Barakaldo, Spain, ¹¹Center for Autoimmune Diseases, Department of Internal Medicine, Careggi Hospital- Florence, Florence, Italy, ¹²Department of Rheumatology, VU University Medical Center, Amsterdam, Netherlands, ¹³Rheumatology Unit, University of Pisa, Pisa, Italy, ¹⁴Rheumatology Unit, San Camillo-Forlanini Hospital, Rome, Rome, Italy, ¹⁵Department of Internal Medicine, Rheumatology Division, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey, ¹⁶Department of Rheumatology, University of Debrecen Medical and Health Sciences Center, Debrecen, Hungary, ¹⁷Department of Rheumatology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark, ¹⁸Hospital Universitari de Reus, Spain, Reus, Spain, ¹⁹ClinTRID, Department of Medicine, Karolinska Institute, Stockholm, Sweden
Background/Purpose: Rituximab (Rituxan, Mabthera; RTX) has not been approved for use in SLE, but uncontrolled observations have suggested efficacy in some patients and the medication…
Abstract Number: 1007 • 2013 ACR/ARHP Annual Meeting
Dose Of Corticosteroid, Risk Of Adverse Events and Healthcare Resource Utilization In Systemic Lupus Erythematosus
Wei-Shi Yeh¹, Shih-Yin Chen², Kathleen McCarty³, Qian Li², Yuan-Chi Lee² and Nathalie Franchimont³, ¹Biogen Idec, Cambridge, MA, ²United BioSource Corporation, Lexington, MA, ³Biogen Idec Inc., Weston, MA
Background/Purpose: Gluco-corticosteroids (GCs) are frequently used to treat autoimmune disease and their chronic use has long been known to cause adverse events (AEs). The purpose…
Abstract Number: 573 • 2013 ACR/ARHP Annual Meeting
Absence Of Estrogen Receptor Alpha Reduces The Number and Function Of Bone Marrow Derived Plasmacytoid Dendritic Cells In Lupus Prone Mice
Jennifer Scott¹, Osama S. Naga², Melissa A. Cunningham³, Jena Wirth³, Jackie G. Eudaly² and Gary S. Gilkeson⁴, ¹Microbiology and Immunology, Medical University of South Carolina, Charleston, SC, ²Medicine/Rheumatology, Medical University of South Carolina, Charleston, SC, ³Med/Rheumatology, MUSC, Charleston, SC, ⁴Department of Medicine, Division of Rheumatology, Medical University of South Carolina, Charleston, SC
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disease that affects women at a 9:1 ratio compared to men. Previous work in our laboratory…
Abstract Number: 2554 • 2013 ACR/ARHP Annual Meeting
In Vitro Fertilization In Systemic Lupus Erythematosus and Antiphospholipid Syndrome: A Series Of 82 Cycles
Pauline Orquevaux¹, Agathe Masseau², Véronique le Guern³, Vanessa Gayet⁴, Danièle Vauthier-Brouzes⁵, Du Boutin⁶, Bertrand Wechsler⁷, Nathalie Morel⁸, Jean Loup Pennaforte¹, Jean-Charles Piette⁹ and Nathalie Costedoat-Chalumeau¹⁰, ¹Hu Robert Debre, CHU Reims, Reims, France, ²Internal Medicine Department, Nantes University Hospital, Nantes, France, ³Department of Internal Medicine, Hôpital Cochin, Paris, France, ⁴Cochin Hospital, Paris, France, ⁵gynecology obstetrical, Pitié Salpétrière Hospital, Paris, France, ⁶Internal Medicine, Assistance Publique-Hôpitaux de Paris, Hopital Pitié-Salpétrière, Paris, France, ⁷Internal Medicine, DHU 2iB Internal Medicine Referal Center for Autoimmune diseases Pitie Hospital, Paris, France, ⁸Internal Medicine, COCHIN, Paris, France, ⁹Department of Internal Medicine 1., CHU Pitié-Salpêtrière, Paris, France, ¹⁰Internal Medicine, Department of Internal Medicine, Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France
Background/Purpose: Patients with systemic lupus erythematosus (SLE) and antiphospholipid syndrome (APS) undergoing in vitro fertilization (IVF) are at increased risk of both hormone-associated flare and…
Abstract Number: 1618 • 2013 ACR/ARHP Annual Meeting
Chromatin Binding In SLE Patients Correlates With The Intensity Of Apoptotic Binding By 9G4+ B Cells
Asiya Seema Chida¹, Quan-Zhen Li², Chandra Mohan³, Youliang Wang¹, Scott Jenks⁴, Louise Hartson¹ and Ignacio Sanz⁵, ¹Medicine, Emory University Medical Center, Atlanta, GA, ²Department of Immunology and Microarray Core Facility, University of Texas Southwestern Medical Center, Dallas, TX, ³University of Houston, Houston, TX, ⁴Allergy, Immunology, and Rheumatology, Emory University School of Medicine, Atlanta, GA, ⁵Rheumatology, Emory University, Atlanta, GA
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a multi-organ autoimmune disease characterised by production of autoantibodies to multiple nuclear antigens, some of which are highly specific…
Abstract Number: 931 • 2012 ACR/ARHP Annual Meeting
Health Care Utilization Among Medicaid Enrollees with Systemic Lupus Erythematosus Preceding the Development of End-Stage Renal Disease: Sociodemographic Variation
Candace H. Feldman¹, Linda T. Hiraki², Graciela S. Alarcon³, Jinoos Yazdany⁴, Jun Liu⁵, Michael A. Fischer⁶, Wolfgang C. Winkelmayer⁷ and Karen H. Costenbader⁸, ¹Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ²Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital/ Harvard School of Public Health, Boston, MA, ³Medicine, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, ⁴Medicine, University of California, San Francisco, San Francisco, CA, ⁵Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Harvard Medical School, Boston, Boston, MA, ⁶Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Boston, MA, ⁷Division of Nephrology, Stanford University School of Medicine, Stanford, CA, ⁸Rheumatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Extreme sociodemographic disparities exist among systemic lupus erythematosus (SLE) patients in the development of end-stage renal disease (ESRD) from lupus nephritis. Better resource allocation…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.